

**Policy** # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Myoelectric Prosthetic Components for the Upper Limb is addressed separately in medical policy 00443

# When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member's contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider a microprocessor-controlled knee in individuals with transfemoral amputation who meet the following requirements to be **eligible for coverage:\*** 

#### Patient Selection Criteria

Coverage eligibility will be considered when all of the following criteria are met:

- Individual has a functional K-Level 3 or above (see Policy Guidelines); AND
- Demonstrated need for daily long distance ambulation at variable rates (generally 400 continuous yards or greater; use of the limb in the home or for basic community ambulation is not sufficient to justify provision of the computerized limb over standard limb applications) OR demonstrated individual need for daily and frequent ambulation on uneven terrain or for regular use on stairs (use of the limb for limited stair climbing in the home or employment environment is not sufficient evidence for prescription of this device over standard prosthetic application); AND
- Physical ability, including adequate cardiovascular and pulmonary reserve, for ambulation at faster than normal walking speed; AND
- Adequate cognitive ability to master use and care requirements for the technology.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

# When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers a powered knee to be **investigational.\*** 

Based on review of available data, the Company considers a microprocessor-controlled or powered ankle-foot to be **investigational.\*** 

Based on review of available data, the Company considers a microprocessor-controlled knee in individuals who do not meet these criteria. to be **investigational.\*** 

### **Policy Guidelines**

Amputees should be evaluated by an independent, qualified professional to determine the most appropriate prosthetic components and control mechanism. A trial period may be indicated to evaluate the tolerability and efficacy of the prosthesis in a real-life setting. Decisions about the potential benefits of microprocessor knees involve multiple factors including activity levels and the individual's physical and cognitive ability. An individual's need for daily ambulation of at least 400 continuous yards, daily and frequent ambulation at variable cadence or on uneven terrain (eg, gravel, grass, curbs), and daily and frequent use of ramps and/or stairs (especially stair descent) should be considered as part of the decision. Typically, the daily and frequent need of 2 or more of these activities would be needed to show benefit.

#### **Individual Selection and Identification**

For individuals in whom the potential benefits of the microprocessor knees are uncertain, individuals may first be fitted with a standard prosthesis to determine their level of function with the standard device.

### **Medicare Functional Classification Levels (K levels)**

- Level 0: Does not have the ability or potential to ambulate or transfer safely with or without assistance and a prosthesis does not enhance their quality of life or mobility
- Level 1: Has the ability or potential to use a prosthesis for transfers or ambulation on level surfaces at fixed cadence. Typical of the limited and unlimited household ambulator.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

- Level 2: Has the ability or potential for ambulation with the ability to traverse low level environmental barriers such as curbs, stairs, or uneven surfaces. Typical of the limited community ambulator.
- Level 3: Has the ability or potential for ambulation with variable cadence. Typical of the community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic, or exercise activity that demands prosthetic utilization beyond simple locomotion.
- Level:4 Has the ability or potential for prosthetic ambulation that exceeds basic ambulation skills, exhibiting high impact, stress, or energy levels. Typical of the prosthetic demands of the child, active adult, or athlete.

The following are guidelines from the Veterans Health Administration Prosthetic Clinical Management Program Clinical Practice Recommendations for Microprocessor Knees.

- A. Contraindications for the use of the microprocessor knee should include the following:
  - Any condition that prevents socket fitting, such as a complicated wound or intractable pain which precludes socket wear
  - Inability to tolerate the weight of the prosthesis
  - Medicare level K0-no ability or potential to ambulate or transfer
  - Medicare level K1-limited ability to transfer or ambulate on level ground at fixed cadence
  - Medicare level K2-limited community ambulator who does not have the cardiovascular reserve, strength, and balance to improve stability in stance to permit increased independence, less risk of falls, and potential to advance to a less restrictive walking device
  - Inability to use swing and stance features of the knee unit
  - Poor balance or ataxia that limits ambulation
  - Significant hip flexion contracture (>20°)
  - Significant deformity of remaining limb that would impair the ability to stride
  - Limited cardiovascular and/or pulmonary reserve or profound weakness
  - Limited cognitive ability to understand gait sequencing or care requirements
  - Long-distance or competitive running
  - Falls outside of recommended weight or height guidelines of the manufacturer

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

- Specific environmental factors such as excessive moisture or dust, or inability to charge the prosthesis
- Extremely rural conditions where maintenance ability is limited.
- B. Indications for the use of the microprocessor knee should include the following:
  - Adequate cardiovascular and pulmonary reserve to ambulate at variable cadence
  - Adequate strength and balance in stride to activate the knee unit
  - Should not exceed the weight or height restrictions of the device
  - Adequate cognitive ability to master technology and gait requirements of the device
  - Hemi-pelvectomy through knee-disarticulation level of amputation, including bilateral; lower-extremity amputees are candidates if they meet functional criteria as listed
  - The individual is an active walker and requires a device that reduces energy consumption to permit longer distances with less fatigue
  - Daily activities or job tasks that do not permit full focus of concentration on knee control and stability-such as uneven terrain, ramps, curbs, stairs, repetitive lifting, and/or carrying
  - Medicare level K2-limited community ambulator, but only if improved stability in stance permits increased independence, less risk of falls, and potential to advance to a less restrictive walking device, and the individual has the cardiovascular reserve, strength, and balance to use the prosthesis. The microprocessor enables fine-tuning and adjustment of the hydraulic mechanism to accommodate the unique motor skills and demands of the functional level K2 ambulator.
  - Medicare level K3-unlimited community ambulator
  - Medicare level K4-active adult athlete who needs to function as a K3 level in daily activities
  - Potential to lessen back pain by providing more secure stance control, using less muscle control to keep the knee stable
  - Potential to unload and decrease stress on remaining limb
  - Potential to return to an active lifestyle.
- C. Physical and Functional Fitting Criteria for New Amputees:
  - New amputees may be considered if they meet certain criteria as outlined above
  - Premorbid and current functional assessment important determinant
  - Requires stable wound and ability to fit the socket

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

• Immediate postoperative fit is possible

• Must have potential to return to an active lifestyle

### **Background/Overview**

### **Lower-Extremity Prosthetics**

More than 100 different prosthetic ankle-foot and knee designs are currently available. The choice of the most appropriate design may depend on the individual's underlying activity level. For example, the requirements of a prosthetic knee in an elderly, largely homebound individual will differ from those of a younger, active person. Key elements of prosthetic knee design involve providing stability during both the stance and swing phase of the gait. Prosthetic knees vary in their ability to alter the cadence of the gait, or the ability to walk on rough or uneven surfaces. In contrast to more simple prostheses, which are designed to function optimally at 1 walking cadence, fluid and hydraulic-controlled devices are designed to allow amputees to vary their walking speed by matching the movement of the shin portion of the prosthesis to the movement of the upper leg. For example, the rate at which the knee flexes after "toe-off" and then extends before heel strike depends in part on the mechanical characteristics of the prosthetic knee joint. If the resistance to flexion and extension of the joint does not vary with gait speed, the prosthetic knee extends too quickly or too slowly relative to the heel strike if the cadence is altered. When properly controlled, hydraulic or pneumatic swing-phase controls allow the prosthetist to set a pace adjusted to the individual amputee, from very slow to a race-walking pace. Hydraulic prostheses are heavier than other options and require gait training; for these reasons, these prostheses are prescribed for athletic or fit individuals. Other design features include multiple centers of rotation, referred to as "polycentric knees." The mechanical complexity of these devices allows engineers to optimize selected stance and swing-phase features.

### FDA or Other Governmental Regulatory Approval

### U.S. Food and Drug Administration (FDA)

According to the manufacturers, microprocessor-controlled prostheses are considered a class I device by the FDA and are exempt from 510(k) requirements. This classification does not require submission of clinical data regarding efficacy but only notification of FDA prior to marketing. FDA product codes: ISW, KFX.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

# Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Microprocessor-controlled prostheses use feedback from sensors to adjust joint movement on a real-time as-needed basis. Active joint control is intended to improve safety and function, particularly for individuals who can maneuver on uneven terrain and with variable gait.

### **Summary of Evidence**

For individuals who have a transfemoral amputation who receive a prosthesis with a microprocessor-controlled knee, the evidence includes a number of within-subject comparisons of microprocessor-controlled knees versus non-microprocessor-controlled knee joints and systematic reviews of these studies. Relevant outcomes are functional outcomes, health status measures, and quality of life. For K3- and K4-level amputees, studies have shown an objective improvement in function on some outcome measures, particularly for hill and ramp descent, and strong individual preference for microprocessor-controlled prosthetic knees. Benefits include a more normal gait, increased stability, and a decrease in falls. The evidence in Medicare level K2 ambulators suggests that a prosthesis with stance control only can improve activities that require balance and improve walking in this population. For these reasons, a microprocessor-controlled knee may provide incremental benefit for these individuals. The potential to achieve a higher functional level with a microprocessor-controlled knee includes having the appropriate physical and cognitive ability to use the advanced technology. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a transfemoral amputation who receive a prosthesis with a powered knee, the evidence includes no data. Relevant outcomes are functional outcomes, health status measures, and quality of life. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

For individuals who have a tibial amputation who receive a prosthesis with a microprocessor-controlled ankle-foot, the evidence includes limited data. Relevant outcomes are functional outcomes, health status measures, and quality of life. The limited evidence available to date does not support an improvement in functional outcomes using microprocessor-controlled ankle-foot prostheses compared with standard prostheses although quality of life improvements was noted in 1 small study. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a tibial amputation who receive a prosthesis with a powered ankle-foot, the evidence includes limited data. Relevant outcomes are functional outcomes, health status measures, and quality of life. The limited evidence available to date does not support an improvement in functional outcomes using powered ankle-foot prostheses compared with standard prostheses. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

# **Supplemental Information**

# **Practice Guidelines and Position Statements Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

#### U.S Department of Veterans Affairs/Department of Defense

In 2019, the Veterans Affairs/Department of Defense Clinical Practice Guideline for Rehabilitation of Individuals with Lower Limb Amputation made the following recommendations:

"We suggest offering microprocessor knee units over non-microprocessor knee units for ambulation to reduce risk of falls and maximize patient satisfaction. There is insufficient evidence to recommend for or against any particular socket design, prosthetic foot categories, and suspensions and interfaces. (From Table 1. Clinical practice guideline evidence-based recommendations and evidence strength)."

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

#### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

### **Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

#### **Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 1.

**Table 1. Summary of Key Trials** 

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT03204513	Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social Interaction	15	Dec 2024
NCT04630457	Safety and Effectiveness of Electronically Controlled Prosthetic Ankle in Patients With Transtibial Amputation	42	Dec 2024
NCT04784429	Assessing Outcomes With Microprocessor Knee Utilization in a K2 Population (ASCENT K2)	107	Dec 2026
NCT05267639	Clinical Outcomes With Passive MPKs vs. Powered Prosthetic Knees	12	Apr 2024
Unpublished			
NCT04112901	Activity, Mobility, Social Functioning, Mental Health and Quality of Life Outcomes in Limited Mobility Transfemoral and Knee Disarticulation Amputees Using Microprocessor-Controlled	330	May 2020

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

NCT No.	Trial Name	Planned Enrollment	Completion Date
	Knees or Non-Microprocessor Controlled Knees in the United Kingdom: A Cohort Study		

NCT: national clinical trial.

### **References**

- 1. Flynn K. Short Report: Computerized lower limb prosthesis (VA Technology Assessment Program). No. 2. Boston, MA: Veterans Health Administration; 2000.
- 2. Thibaut A, Beaudart C, Maertens DE Noordhout B, et al. Impact of microprocessor prosthetic knee on mobility and quality of life in patients with lower limb amputation: a systematic review of the literature. Eur J Phys Rehabil Med. Jun 2022; 58(3): 452-461. PMID 35148043
- 3. Hahn A, Bueschges S, Prager M, et al. The effect of microprocessor controlled exo-prosthetic knees on limited community ambulators: systematic review and meta-analysis. Disabil Rehabil. Dec 2022; 44(24): 7349-7367. PMID 34694952
- 4. Theeven P, Hemmen B, Rings F, et al. Functional added value of microprocessor-controlled knee joints in daily life performance of Medicare Functional Classification Level-2 amputees. J Rehabil Med. Oct 2011; 43(10): 906-15. PMID 21947182
- 5. Theeven PJ, Hemmen B, Geers RP, et al. Influence of advanced prosthetic knee joints on perceived performance and everyday life activity level of low-functional persons with a transfemoral amputation or knee disarticulation. J Rehabil Med. May 2012; 44(5): 454-61. PMID 22549656
- 6. Burnfield JM, Eberly VJ, Gronely JK, et al. Impact of stance phase microprocessor-controlled knee prosthesis on ramp negotiation and community walking function in K2 level transfemoral amputees. Prosthet Orthot Int. Mar 2012; 36(1): 95-104. PMID 22223685
- 7. Orendurff MS, Segal AD, Klute GK, et al. Gait efficiency using the C-Leg. J Rehabil Res Dev. 2006; 43(2): 239-46. PMID 16847790
- 8. Klute GK, Berge JS, Orendurff MS, et al. Prosthetic intervention effects on activity of lower-extremity amputees. Arch Phys Med Rehabil. May 2006; 87(5): 717-22. PMID 16635636
- 9. Williams RM, Turner AP, Orendurff M, et al. Does having a computerized prosthetic knee influence cognitive performance during amputee walking? Arch Phys Med Rehabil. Jul 2006; 87(7): 989-94. PMID 16813788

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

- 10. Hafner BJ, Smith DG. Differences in function and safety between Medicare Functional Classification Level-2 and -3 transfemoral amputees and influence of prosthetic knee joint control. J Rehabil Res Dev. 2009; 46(3): 417-33. PMID 19675993
- 11. Highsmith MJ, Kahle JT, Miro RM, et al. Ramp descent performance with the C-Leg and interrater reliability of the Hill Assessment Index. Prosthet Orthot Int. Oct 2013; 37(5): 362-8. PMID 23327837
- 12. Howard CL, Wallace C, Perry B, et al. Comparison of mobility and user satisfaction between a microprocessor knee and a standard prosthetic knee: a summary of seven single-subject trials. Int J Rehabil Res. Mar 2018; 41(1): 63-73. PMID 29293160
- 13. Hafner BJ, Willingham LL, Buell NC, et al. Evaluation of function, performance, and preference as transfemoral amputees transition from mechanical to microprocessor control of the prosthetic knee. Arch Phys Med Rehabil. Feb 2007; 88(2): 207-17. PMID 17270519
- 14. Kaufman KR, Bernhardt KA, Symms K. Functional assessment and satisfaction of transfemoral amputees with low mobility (FASTK2): A clinical trial of microprocessor-controlled vs. nonmicroprocessor-controlled knees. Clin Biomech (Bristol, Avon). Oct 2018; 58: 116-122. PMID 30077128
- 15. Kaufman KR, Levine JA, Brey RH, et al. Gait and balance of transfemoral amputees using passive mechanical and microprocessor-controlled prosthetic knees. Gait Posture. Oct 2007; 26(4): 489-93. PMID 17869114
- 16. Kaufman KR, Levine JA, Brey RH, et al. Energy expenditure and activity of transfemoral amputees using mechanical and microprocessor-controlled prosthetic knees. Arch Phys Med Rehabil. Jul 2008; 89(7): 1380-5. PMID 18586142
- 17. Johansson JL, Sherrill DM, Riley PO, et al. A clinical comparison of variable-damping and mechanically passive prosthetic knee devices. Am J Phys Med Rehabil. Aug 2005; 84(8): 563-75. PMID 16034225
- 18. Carse B, Scott H, Brady L, et al. Evaluation of gait outcomes for individuals with established unilateral transfemoral amputation following the provision of microprocessor controlled knees in the context of a clinical service. Prosthet Orthot Int. Jun 01 2021; 45(3): 254-261. PMID 34016870
- 19. Alzeer AM, Bhaskar Raj N, Shahine EM, et al. Impacts of Microprocessor-Controlled Versus Non-microprocessor-Controlled Prosthetic Knee Joints Among Transfemoral Amputees on Functional Outcomes: A Comparative Study. Cureus. Apr 2022; 14(4): e24331. PMID 35607529

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

- 20. Hofstad C, Linde H, Limbeek J, et al. Prescription of prosthetic ankle-foot mechanisms after lower limb amputation. Cochrane Database Syst Rev. 2004; 2004(1): CD003978. PMID 14974050
- 21. Alimusaj M, Fradet L, Braatz F, et al. Kinematics and kinetics with an adaptive ankle foot system during stair ambulation of transtibial amputees. Gait Posture. Oct 2009; 30(3): 356-63. PMID 19616436
- 22. Fradet L, Alimusaj M, Braatz F, et al. Biomechanical analysis of ramp ambulation of transtibial amputees with an adaptive ankle foot system. Gait Posture. Jun 2010; 32(2): 191-8. PMID 20457526
- 23. Darter BJ, Wilken JM. Energetic consequences of using a prosthesis with adaptive ankle motion during slope walking in persons with a transtibial amputation. Prosthet Orthot Int. Feb 2014; 38(1): 5-11. PMID 23525888
- 24. Gailey RS, Gaunaurd I, Agrawal V, et al. Application of self-report and performance-based outcome measures to determine functional differences between four categories of prosthetic feet. J Rehabil Res Dev. 2012; 49(4): 597-612. PMID 22773262
- 25. Delussu AS, Brunelli S, Paradisi F, et al. Assessment of the effects of carbon fiber and bionic foot during overground and treadmill walking in transtibial amputees. Gait Posture. Sep 2013; 38(4): 876-82. PMID 23702342
- 26. Thomas-Pohl M, Villa C, Davot J, et al. Microprocessor prosthetic ankles: comparative biomechanical evaluation of people with transtibial traumatic amputation during standing on level ground and slope. Disabil Rehabil Assist Technol. Jan 2021; 16(1): 17-26. PMID 31535903
- 27. Colas-Ribas C, Martinet N, Audat G, et al. Effects of a microprocessor-controlled ankle-foot unit on energy expenditure, quality of life, and postural stability in persons with transtibial amputation: An unblinded, randomized, controlled, cross-over study. Prosthet Orthot Int. Dec 01 2022; 46(6): 541-548. PMID 36515900
- 28. Au S, Berniker M, Herr H. Powered ankle-foot prosthesis to assist level-ground and stair-descent gaits. Neural Netw. May 2008; 21(4): 654-66. PMID 18499394
- 29. Ferris AE, Aldridge JM, Rábago CA, et al. Evaluation of a powered ankle-foot prosthetic system during walking. Arch Phys Med Rehabil. Nov 2012; 93(11): 1911-8. PMID 22732369
- 30. Herr HM, Grabowski AM. Bionic ankle-foot prosthesis normalizes walking gait for persons with leg amputation. Proc Biol Sci. Feb 07 2012; 279(1728): 457-64. PMID 21752817
- 31. Mancinelli C, Patritti BL, Tropea P, et al. Comparing a passive-elastic and a powered prosthesis in transtibial amputees. Annu Int Conf IEEE Eng Med Biol Soc. 2011; 2011: 8255-8. PMID 22256259

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

- 32. Cacciola CE, Kannenberg A, Hibler KD, Howell J. Impact of a Powered Prosthetic Ankle-Foot Component on Musculoskeletal Pain in Individuals with Transtibial Amputation: A Real-World Cross-Sectional Study with Concurrent and Recalled Pain and Functional Ratings. J Prosthet Orthot. 2022. doi: 10.1097/JPO.0000000000000442.
- 33. Webster JB, Crunkhorn A, Sall J, et al. Clinical Practice Guidelines for the Rehabilitation of Lower Limb Amputation: An Update from the Department of Veterans Affairs and Department of Defense. Am J Phys Med Rehabil. Sep 2019; 98(9): 820-829. PMID 31419214
- 34. Balk EM, Gazula A, Markozannes G, et al. Lower Limb Prostheses: Measurement Instruments, Comparison of Component Effects by Subgroups, and Long-Term Outcomes [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep. (Comparative Effectiveness Review, No. 213.) Table 1, Lower limb extremity prosthesis Medicare Functional Classification Levels (K levels) Available from: https://www.ncbi.nlm.nih.gov/books/NBK531517/table/ch2.tab1/

# **Policy History**

	<u>,                                    </u>
Original Effecti	ve Date: 07/16/2014
Current Effective	ve Date: 07/08/2024
07/10/2014	Medical Policy Committee review
07/16/2014	Medical Policy Implementation Committee approval. New policy.
08/06/2015	Medical Policy Committee review
08/19/2015	Medical Policy Implementation Committee approval. No change to coverage.
08/04/2016	Medical Policy Committee review
08/17/2016	Medical Policy Implementation Committee approval. No change to coverage.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
08/03/2017	Medical Policy Committee review
08/23/2017	Medical Policy Implementation Committee approval. No change to coverage.
08/09/2018	Medical Policy Committee review
08/15/2018	Medical Policy Implementation Committee approval. Added policy guidelines.
	And added "ankle-foot" to investigational statement.
08/01/2019	Medical Policy Committee review
08/14/2019	Medical Policy Implementation Committee approval. Coverage eligibility
	unchanged.
08/06/2020	Medical Policy Committee review

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

08/12/2020	Medical Policy Implementation Committee approval. Coverage eligibility		
	unchanged.		
06/03/2021	Medical Policy Committee review		
06/09/2021	Medical Policy Implementation Committee approval. Coverage eligibility		
	unchanged.		
06/02/2022	Medical Policy Committee review		
06/08/2022	Medical Policy Implementation Committee approval. Coverage eligibility		
	unchanged.		
10/12/2022	Coding update		
06/01/2023	Medical Policy Committee review		
06/14/2023	Medical Policy Implementation Committee approval. Based on review of available		
	data, the Company considers a microprocessor-controlled knee in individuals who		
	do not meet these criteria. to be investigational. This statement was changed from		
	Not medically necessary to investigational. "Individual has a functional K-Level 3		
	or above" was added to patient selection criteria. Criteria clarified.		
12/12/2023	Coding update		
06/06/2024	Medical Policy Committee review		
06/12/2024	Medical Policy Implementation Committee approval. No change to coverage.		
03/25/2025	Coding update		
	Decision Date: 06/2025		

Next Scheduled Review Date: 06/2025

### **Coding**

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units,

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	No codes
HCPCS	L5615, L5856, L5857, L5858, L5859, L5930, L5969, L5973 Delete code effective 01/01/2024: K1014 Add code effective 04/01/2025: L5827
ICD-10 Diagnosis	All related Diagnoses

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
  - 1. Consultation with technology evaluation center(s);

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.



Policy # 00426

Original Effective Date: 07/16/2014 Current Effective Date: 07/08/2024

- 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
- 3. Reference to federal regulations.

\*\*Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

† Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

**NOTICE:** Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.